We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-1.57%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.47B
AUM Growth
-$458M
Cap. Flow
+$15.5M
Cap. Flow %
0.35%
Top 10 Hldgs %
43.81%
Holding
163
New
19
Increased
16
Reduced
16
Closed
17

Top Buys

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$65.4M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$64M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$58.4M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$56.3M
5
OMGA
Omega Therapeutics, Inc. Common Stock
OMGA
+$43.6M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$65.4M
2
XLRN
Acceleron Pharma
XLRN
+$52.3M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$38.8M
4
SEER icon
Seer Inc
SEER
+$28.8M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$24.3M

Sector Composition

Rank Sector Weight
1 Healthcare 82%
2 Consumer Discretionary 6.51%
3 Financials 0.67%
4 Consumer Staples 0.51%
5 Materials 0.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAX icon
51
Praxis Precision Medicines
PRAX
$8.2B
$22.2M 0.5%
80,000
– –
AUPH icon
52
Aurinia Pharmaceuticals
AUPH
$1.92B
$22.1M 0.5%
1,000,000
– –
KURA icon
53
Kura Oncology
KURA
$793M
$19.7M 0.44%
1,050,000
+450,000
+75% +$8.48M
IMA
54
ImageneBio Inc
IMA
$64M
$19.6M 0.44%
129,126
– –
TSHA icon
55
Taysha Gene Therapies
TSHA
$1.55B
$19.4M 0.43%
1,040,882
– –
VERV
56
DELISTED
Verve Therapeutics
VERV
$18.8M 0.42%
400,000
-100,000
-20% -$5.88M
ALBO
57
DELISTED
Albireo Pharma Inc
ALBO
$18.7M 0.42%
600,000
– –
NEXI
58
DELISTED
NexImmune, Inc. Common Stock
NEXI
$18.2M 0.41%
48,000
– –
NG icon
59
NovaGold Resources
NG
$2.54B
$17.9M 0.4%
2,600,000
– –
ACHL
60
DELISTED
Achilles Therapeutics
ACHL
$17.6M 0.39%
2,255,375
– –
RNAC icon
61
Cartesian Therapeutics
RNAC
$223M
$16.6M 0.37%
133,333
– –
CYPH
62
Cypherpunk Technologies Inc
CYPH
$64.3M
$16M 0.36%
400,000
+100,000
+33% +$1.88M
INTC icon
63
CALL
Intel
INTC
$421B
$16M 0.36%
300,000
-1,000,000
-77% -$54.2M
BABA icon
64
Alibaba
BABA
$276B
$14.8M 0.33%
+100,000
New +$18.2M
RPTX
65
DELISTED
Repare Therapeutics
RPTX
$14.4M 0.32%
550,000
– –
ADAG
66
Adagene
ADAG
$250M
$14.4M 0.32%
1,000,000
– –
APTX
67
DELISTED
Aptinyx Inc. Common Stock
APTX
$14.3M 0.32%
6,116,493
– –
DRNA
68
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$14.1M 0.32%
700,000
-100,000
-13% -$2.76M
BDTX icon
69
Black Diamond Therapeutics
BDTX
$95.7M
$13.9M 0.31%
1,646,517
– –
ZYME icon
70
Zymeworks
ZYME
$1.63B
$13.1M 0.29%
450,000
– –
RLAY icon
71
Relay Therapeutics
RLAY
$3.95B
$12.6M 0.28%
400,000
– –
BBIO icon
72
BridgeBio Pharma
BBIO
$16.7B
$11.7M 0.26%
250,000
-25,000
-9% -$1.34M
AMAM
73
DELISTED
Ambrx Biopharma Inc
AMAM
$11.5M 0.26%
850,000
– –
LENZ
74
LENZ Therapeutics
LENZ
$179M
$11.5M 0.26%
100,000
– –
YMAB
75
DELISTED
Y-mAbs Therapeutics
YMAB
$11.4M 0.26%
400,000
– –
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2021 Portfolio in Review

As of Q3 2021, Artal Group held 163 positions worth $4.47B, down 9.3% from $4.93B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Artal Group's Q3 2021 filing shows 19 new, 16 increased, 16 reduced and 17 closed positions. Its largest new stake was Erasca: 3,172,221 shares worth $67.3M. The largest sale was BeOne Medicines Ltd, an estimated $65.4M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 74% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Artal Group's largest Q3 2021 buy was Erasca: 3,172,221 shares worth $67.3M.
  • Artal Group added most to Mirati Therapeutics, Inc. Common Stock in Q3 2021, an estimated $56.3M increase.
  • Artal Group's biggest Q3 2021 reduction was BeOne Medicines Ltd, cutting an estimated $65.4M.
  • Artal Group fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q3 2021, selling an estimated $38.8M.
  • Artal Group's ten largest holdings make up 44% of its $4.47B portfolio in Q3 2021.
  • Artal Group opened 19 new positions and closed 17 in Q3 2021.
  • Artal Group's portfolio value fell 9.3% quarter-over-quarter to $4.47B.

Based on Artal Group's 13F filing for Q3 2021, filed 12 Nov 2021.